| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
1 company
Gwenn Hansen is Chief Scientific Officer at NRIX. Gwenn Hansen's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.2M at current prices.
Historically, Gwenn Hansen's trades have earned a strong insider score of 70/100 across 35 rated trades. Over a 12-month horizon, 78.6% of those trades were profitable, with an average 12-month return of +22.1%.
The NRIX filings lean toward selling, a net 80,920 shares.
Gwenn Hansen has 50 Form 4 filings on record from November 2020 to October 2026, all as Chief Scientific Officer at Nurix Therapeutics (NRIX), 2020–2026.
The 127 reported transactions were 69 option exercises, 45 open-market sales and 13 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 40 sales worth about $1.6M.
The largest open-market sale was 5,409 shares of NRIX at an average $26.42 on November 2, 2026, about $143K.
6 of the 20 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 14 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 5,409 | $26.42 | $142,900.00 | -4.2% | - | - | |
| Oct 15, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 1,452 | $25.00 | $36,300.00 | -1.2% | - | - | |
| Sep 1, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 1,452 | $25.47 | $36,982.44 | -1.2% | - | - | |
| Aug 5, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 4,356 | $25.00 | $108,900.00 | -3.6% | +8.0% | - | |
| Aug 4, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Scientific Officer | Sell10b5-1 | 4,111 | $24.36 | $100,141.56 | -3.4% | +9.8% | - | |
| Jul 30, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 3,847 | $23.38 | $89,953.63 | -3.1% | +15.6% | - | |
| Jun 25, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Scientific Officer | Sell10b5-1 | 5,394 | $20.00 | $107,880.00 | -4.5% | +6.3% | - | |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 3,214 | $16.65 | $53,497.99 | -2.6% | +41.3% | - | |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 4,895 | $16.60 | $81,249.16 | -5.5% | +1.1% | - | |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 4,087 | $12.80 | $52,300.11 | -5.1% | +39.8% | +112.2% |